Granite Point Capital Management, L.P. Regenxbio Inc. Transaction History

Granite Point Capital Management, L.P.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 05, 2022	BUY	$19.35 - $35.04 $1.16 Million - $2.1 Million	60,000 New	60,000 $1.48 Million
Q1 2019 May 14, 2019	SELL	$40.82 - $62.45 $1.94 Million - $2.97 Million	-47,500 Closed	0 $0
Q3 2018 Nov 13, 2018	SELL	$65.0 - $82.15 $169,000 - $213,590	-2,600 Reduced 5.19%	47,500 $3.59 Million
Q2 2018 Aug 13, 2018	SELL	$27.2 - $74.35 $677,280 - $1.85 Million	-24,900 Reduced 33.2%	50,100 $3.6 Million
Q1 2018 May 15, 2018	BUY	$24.05 - $37.5 $1.8 Million - $2.81 Million	75,000 New	75,000 $2.24 Million

193

42.1M

80.6K

55.2K

Ticker RGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,230,000
Market Cap $458M
Description
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...

Get notified when there are updates to the investment portfolio of Granite Point Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Granite Point Capital Management, L.P. with notifications on news.